Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- Check3 days agoChange DetectedAdded 'Gastrointestinal stromal tumor' as a disease term and a Resources section linking Genetic and Rare Diseases Information Center to the page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The previous revision is no longer active.SummaryDifference0.0%

- Check53 days agoChange DetectedUpdated metadata shows a new revision label (v3.4.2) and added dates (2026-02-05, 2026-12, 2026-01-16, 2026-01). Older notices including the government funding lapse message and the previous revision (v3.4.1) were removed.SummaryDifference0.3%

- Check61 days agoChange DetectedAdded a site-wide funding/status notice indicating government funding impacts and updated the page revision from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedA glossary toggle was added and several metadata/versioning fields were updated or renamed (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), with the previous QC wording and No FEAR Act data removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.